Literature DB >> 27667001

18F-FDG PET/CT and sentinel lymph node biopsy in the staging of patients with cervical and endometrial cancer. Role of dual-time-point imaging.

M Mayoral1, P Paredes2, B Domènech3, P Fusté4, S Vidal-Sicart2, A Tapias3, A Torné5, J Pahisa5, J Ordi6, F Pons2, F Lomeña2.   

Abstract

OBJECTIVE: Definitive staging for cervical (CC) and endometrial cancer (EC) takes place once surgery is performed. The aim of this study was to evaluate the role of PET/CT in detecting lymphatic metastasis in patients with CC and EC using dual-time-point imaging (DPI), taking the histopathological results of sentinel lymph node (SLN) and lymphadenectomy as the reference.
MATERIAL AND METHODS: A prospective study was conducted on 17 patients with early CC, and 13 patients with high-risk EC. The patients had a pre-operative PET/CT, MRI, SLN detection, and lymphadenectomy, when indicated. PET/CT findings were compared with histopathological results.
RESULTS: In the pathology study, 4 patients with CC and 4 patients with EC had lymphatic metastasis. PET/CT showed hypermetabolic nodes in 1 patient with CC, and 5 with EC. Four of these had metastasis, one detected in the SLN biopsy. Four patients who had negative PET/CT had micrometastasis in the SLN biopsy, 1 patient with additional lymph nodes involvement. The overall patient-based sensitivity, specificity, positive and negative predictive values, and accuracy of PET/CT to detect lymphatic metastasis was 20.0%, 100.0%, 100.0%, 87.9%, and 88.2%, respectively, in CC, and 57.1%, 88.9%, 66.7%, 84.2% and 80.0%, respectively, in EC. DPI showed higher retention index in malignant than in inflammatory nodes, although no statistically significant differences were found.
CONCLUSIONS: PET/CT has low sensitivity in lymph node staging of CC and EC, owing to the lack of detection of micrometastasis. Thus, PET/CT cannot replace SLN biopsy. Although no statistically significant differences were found, DPI may help to differentiate between inflammatory and malignant nodes.
Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Cáncer de cérvix; Cáncer de endometrio; Dual-time-point imaging; Endometrial cancer; Ganglio centinela; Imagen dual-time-point; PET/CT; PET/TC; Sentinel lymph node

Mesh:

Substances:

Year:  2016        PMID: 27667001     DOI: 10.1016/j.remn.2016.07.003

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  4 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  Influence of 99m-Tc-Nanocolloid Activity Concentration on Sentinel Lymph Node Detection in Endometrial Cancer: A Quantitative SPECT/CT Study.

Authors:  Samine Sahbai; Francesco Fiz; Florin Taran; Sara Brucker; Diethelm Wallwiener; Juergen Kupferschlaeger; Christian La Fougère; Helmut Dittmann
Journal:  Diagnostics (Basel)       Date:  2020-09-16

3.  Comparison of positron emission tomography with computed tomography examination with histopathological assessment of pelvic lymph nodes in patients with cervical cancer treated surgically.

Authors:  Kamila Kaźmierczak; Witold Cholewiński; Błażej Nowakowski
Journal:  Contemp Oncol (Pozn)       Date:  2021-09-20

4.  The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Authors:  Juan Zhou; Wen-Wen Zhang; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Yan Wang; Qiong-Hua Chen
Journal:  Cancer Manag Res       Date:  2017-07-18       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.